INTRODUCTION
• Prostate cancer and its treatment can have a significant impact on health-related quality of life (HRQoL) as shown by responses to disease-specific questionnaires, such as Functional Assessment of Cancer Therapy-Prostate (FACT-P).
• Disease-specific measures, such as FACT-P, are commonly collected within clinical studies, but as preference-based valuations are not available for most of these disease-specific instruments, they cannot be used directly in cost-utility analysis.
• Mapping from health status measures onto generic preference-based measures is becoming a common solution when health state utility values are not directly available for cost-utility analysis.
• To overcome a lack of appropriate preference-based HRQoL data in metastatic castration-resistant prostate cancer (mCRPC), Skaltsa et al 2014 1 used a dataset of symptomatic patients who failed chemotherapy with docetaxel to generate algorithms that map FACT-P scores to EQ-5D utilities. Authors considered a range of model specifications and 3 statistical modelling techniques: (1) generalized estimating equations (GEE), (2) two-part model (TPM) combining logistic regression and GEE, and (3) separate mapping algorithms for patients with poor health and good health (group-specific model [GSM] ). Authors concluded that all 3 models performed well, but that the GSM had the best predictive performance.
• While Skaltsa et al validated the algorithms using a within-sample approach, it was not possible to validate the algorithms using external samples at the time when the algorithm was developed. External validation of mapping algorithms is, however, recommended to be performed in a variety of out-of-sample populations before their routine use.
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OBJECTIVE
• Evaluate the predictive performance of a published mapping algorithm 1 for predicting EQ-5D values from the prostate cancer-specific instrument FACT-P using an external dataset with asymptomatic or minimally to mildly symptomatic chemotherapy-naïve mCRPC patients.
METHODS
• The validation sample came from PREVAIL, a phase 3 trial of enzalutamide (XTANDI ® ) vs placebo in men with asymptomatic or minimally to mildly symptomatic chemotherapy-naïve mCRPC who progressed on androgen deprivation therapy. 3 • EQ-5D and FACT-P questionnaires were collected at baseline, week 13, week 25, and at every subsequent 12 weeks. EQ-5D utility index was calculated using the preference-based algorithm derived from the UK general population. 4 • We have applied the best model of each technique reported in Skaltsa et al 2014 1 to the PREVAIL dataset. The coefficients of the model equations for the original algorithm are provided in Table 1 . Predicted values exceeding the minimum and maximum values were truncated (-0.594 and 1).
• Model performance was assessed by the mean error (ME), mean absolute error (MAE), and root mean square error (RMSE). The percentage of values correctly predicted within 0.05 and 0.1 of the observed utility were also calculated.
• In order to determine whether the degree of error is evenly distributed across the entire range of the EQ-5D utility index, ME, MAE, and RMSE were also reported for subsets such as EQ-5D ≤ 0, 0 < EQ-5D ≤ 0.25, 0.25 < EQ-5D ≤ 0.5, 0.5 < EQ-5D ≤ 0.75, and 0.75 < EQ-5D ≤ 1.
• Finally, a Bland-Altman analysis was performed to see how well the observed and predicted EQ-5D utility index agreed and if there appeared to be any systematic measurement bias in the predicted utility index. ECOG PS = Eastern Cooperative Oncology Group Performance Status; FACT-P = Functional Assessment of Cancer Therapy-Prostate; GEE = generalized estimating equations; GSM = group-specific model; TPM = two-part model; WB = well-being.
RESULTS
• The validation sample included 1713 patients (n = 872 enzalutamide, n = 841 placebo) with non-missing EQ-5D utility index scores. • Patient baseline characteristics are shown in Table 2 . Descriptive statistics for FACT-P and EQ-5D scores in the 2 samples are presented in Table 3 , and a histogram of EQ-5D utility index scores across all visits in the validation sample are shown in Figure 1 . Patients in the validation sample were healthier than in the estimation sample, indicated by higher mean FACT-P domain and total scores and mean EQ-5D values.
Percentage of perfect health (EQ-5D utility index score = 1.0) was 37% across all visits (ceiling effect).
• All 3 models yield accurate predictions comparable to those obtained from the estimation sample (Table 4) .
• All models predict well for milder health states, but over predict for the more severe ones ( Table 4) .
• Similar percentages of values that correctly predicted within 0.05 and 0.1 of the observed utility were obtained for all models; 32%-36% of predictions were within 0.05 and approximately 58% within 0.10 of the observed utility value ( Table 5 ).
• The Bland-Altman analysis (Figures 2A-C) showed reasonable agreement for higher EQ-5D utility index values, but poor agreement for patients with EQ-5D utility index values approximately ≤ 0.5 in the validation dataset. The dashed lines show the 95% confidence agreement band. GEE = generalized estimating equations.
DISCUSSION
• Using FACT-P subscales and baseline characteristics, a mapping function enables the calculation of preference-based HRQoL scores for use in cost-effectiveness analyses when EQ-5D data are missing.
• Furthermore, the mapping function was validated for use in a population with the same disease, but in an earlier treatment setting. Out-of-sample predictive accuracy of the mapping algorithm compared well to the within-sample predictive accuracy.
• Our analysis showed that all 3 mapping techniques provided similar and satisfactory mean prediction accuracy, although results exhibited an over prediction for more severe states, as is common in mapping exercises. This could be due to the sparseness of data in the low utility value range, which is typical in clinical trials.
• Attempts to validate mapping algorithms to external samples have been made 5 and showed that the relationship between oncology-specific scores and EQ-5D values was not stable across different data sets corresponding to different oncology settings.
• The previously developed algorithm maps the prostate cancer-specific questionnaire FACT-P, thus it could only be applied and validated in a prostate cancer population. Our results demonstrate satisfactory external predictive power of the algorithm. • In conclusion, direct mapping using the previously developed algorithm to predict EQ-5D values from the FACT-P measure can be used in patients with mCRPC; however, caution should be exercised when applying the algorithms to mCRPC patients with severe health states.
